BPR-890 is a potent agonist of CB1. BPR-890 exhibits excellent CB2/1 selectivity and has in vivo efficacy in diet-induced obese mouse model.

AM11542 is a orthosteric agonist of cannabinoid receptor 1 (CB1), with a reported binding affinity (Ki) of 0.11 nM. AM11542 can be used for the study of CB1 receptor activation and related allosteric modulation mechanisms.

BMS-812204 is a highly selective CB-1 receptor antagonist. BMS-812204 is promising for research of obesity and metabolic disorders.

AM12814 is a potent and partial CB1 and CB2 agonist with Ki values of 0.7 nM and 3.4 nM. AM12814 can inhibit cAMP accumulation and recruitse β-arrestin 2. AM12814 exhibits cannabimimetic effects. AM12814 can be used for the research of neurological disease, suah as catalepsy.

AM11638 is an endocannabinoid analog targeting cannabinoid receptors (CB1 and CB2 receptors) with analgesic effects. AM11638 is promising for research of neurological diseases and inflammation-related diseases.

MDA-19 N-(5-hydroxyhexyl) is a cannabinoid receptor modulator targeting CB1R/CB2R. MDA-19 N-(5-hydroxyhexyl) is used to study neurological diseases, cancer, and pain regulation.

ISAM-CG557 is a selective CB2R agonist, with a Ki of 54.6 nM. ISAM-CG557 reduces intracellular ROS levels and caspase activity. ISAM-CG557 exhibits significant MAPK bias and moderate G-protein bias, with CB2R EC50s of 0.60 nM (cAMP), 60.9 nM (β-arrestin) and 0.03 nM (MAPK). ISAM-CG557 exerts potent anti-inflammatory effects by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines in cells. ISAM-CG557 can be used for the study of neuroinflammatory and neurodegenerative disorders.

CHO-4’Me-5’Br-FUBOXPYRA (CH-FUBBMPDORA) is an oxopyridine carboxamide that shares a similar structure to known synthetic cannabinoids. CHO-4’Me-5’Br-FUBOXPYRA demonstrates limited activation potential at both cannabinoid receptors CB1 and CB2.

CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with Ki of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer.

UVI3502 is a cannabinoid receptor 1 (CB1) antagonist with an IC50 value of 4641 nM for CB1 and approximately 16200 nM for CB2. UVI3502 blocks Gi/o protein coupling induced by the agonist CP55,940. UVI3502 is promising for research of endocannabinoid system-related diseases in the central nervous system (such as cognitive impairment and neurodegenerative diseases).

L-759656 is a selective cannabinoid CB2 receptor agonist, with the Ki of 11.8 nM for the human CB2 receptor. L-759656 potently inhibits Forskolin-stimulated cyclic AMP production in Chinese Hamster Ovary (CHO) cells, with an EC50 of 3.1 nM. L-759656 can be used for the study of immune-related diseases and inflammatory diseases.

MK-5596 is an efficient, selective and orally active CB1R (IC50 = 1.0 nM, EC50 = 5.8 nM) inverse agonist. MK-5596 has weak hERG inhibitory activity. MK-5596 has strong weight loss and appetite suppression effects. MK-5596 has a certain inhibitory effect on CYP enzymes (CYP3A4: IC50 = 3.3 μM, CYP2C8: IC50 = 11 μM, CYP2C9: IC50 = 18 μM, CYP2D6: IC50 = 6 μM). MK-5596 can be used for research on conditions such as obesity.

(±)5(6)-EET Ethanolamide is a metabolite of Anandamide generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has Ki values of 11.4 μM and 8.9 nM for human CB1 and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation.

BI-5756 is a CETP inhibitor and cannabinoid receptor 1 (CB1) agonist. BI-5756 can significantly increase HDL-C levels and reduce LDL-C levels. BI-5756 can also enhance the function of regulatory T cells while maintaining T cell-mediated anti-tumor activity. BI-5756 can directly inhibit the growth of tumor cells and upregulate the expression of MHC I, MHC II, and CD80 on tumor cells. BI-5756 has a protective effect in graft-versus-host disease models. BI-5756 can be used in research on tumors, graft-versus-host disease, and metabolic diseases.

Δ9-THCP acetate (Δ9-Tetrahydrocannabiphorol acetate) is structurally similar to known phytocannabinoids.

Δ9-THCBA-A (Δ9-Tetrahydrocannabinolic acid-C4) is structurally similar to known phytocannabinoids.

Δ9-Tetrahydrocannabiorcol is structurally similar to known phytocannabinoids.

Δ8-THCPA-A (Δ8-Tetrahydrocannabiphorolic acid) is structurally similar to known phytocannabinoids.

Δ8-THCP (Δ8-Tetrahydrocannabiphorol; n-Heptyl Δ8-THC) (Compound 1a) is a semisynthetic cannabinoid that serves as an analytical reference standard and exhibits affinity for the CB1 receptor.

Δ8-THC-ethyl (Ethyl-Δ8-Tetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Δ8-THCBA-A (Δ8-Tetrahydrocannabibutolic acid A) is structurally similar to known phytocannabinoids.

Δ8-THCB (∆8-Tetrahydrocannabutol) is a structural analog of phytocannabinoids. Δ8-THCB is also an analog of Δ8-tetrahydrocannabinol.

Δ8-THC methyl ether (compound 3) shows a good docking score (-10.167 kcal/mol) for CB2 receptor. Δ8-THC methyl ether has antinociceptive activity in mice.

Δ8-THC Glucuronide is a phytocannabinoid metabolite.

Δ8-Tetrahydrocannabivarin is a cannabinoid.

Δ8-iso-THC is structurally similar to known phytocannabinoids.

Δ4-Iso-THC (Δ4-Iso-tetrahydrocannabinol) is a cannabidiol derivative with potential cytotoxicity targeting cancer cells.

Δ4(8)-iso-THC (Δ4(8)-Isotetrahydrocannabinol) is structurally similar to known phytocannabinoids.

Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.

Rezosicone is the antagonist for cannabinoid CB1 receptor.